Table 3.
The top 10 journals with most citations per paper per year in melanoma immunotherapy between 2010 and 2022.
Journals with most papers | Paper number | Top-Paper number | TPR (2010-2020) a | Total citation | Citation per paper | Citation per paper per year b | Local citation c | IF (2020) |
---|---|---|---|---|---|---|---|---|
N. Engl. J. Med. | 17 | 16 | 100.0% | 42682 | 2510.7 | 356.9 | 6181 | 91.25 |
Science | 6 | 3 | 100.0% | 4520 | 753.3 | 202 | 1180 | 47.73 |
Nature | 3 | 1 | 33.3% | 751 | 250.3 | 112.7 | 1566 | 49.96 |
Lancet | 4 | 2 | 50.0% | 2171 | 542.8 | 102.3 | 690 | 79.32 |
Cell | 5 | 3 | 60.0% | 2481 | 496.2 | 100.1 | 968 | 41.58 |
Lancet Oncol. | 25 | 14 | 70.0% | 9784 | 391.4 | 72.8 | 2050 | 41.32 |
J. Exp. Med. | 3 | 3 | 100.0% | 2262 | 754 | 71 | 894 | 14.31 |
JAMA | 2 | 1 | 50.0% | 710 | 355 | 57.8 | 234 | 56.27 |
Sci. Transl. Med. | 7 | 3 | 42.9% | 2160 | 308.6 | 45.9 | 405 | 17.99 |
JAMA Oncol. | 8 | 1 | 16.7% | 1085 | 135.6 | 44.1 | 450 | 31.78 |
Percentage of top-cited papers among all papers in a journal. The time span was from 2010 to 2020 (the year of publication of the most recent top-cited paper.
Papers published in 2022 were not included for calculating citation per paper per year.
Citation number in the current dataset (papers in melanoma immunotherapy between 2010 and 2022).